▼ bearish
Impact
PhaseApproved
Time to marketAlready approved. However, Indivior discontinued all marketing and promotion of OPVEE in September 2025 after a settlement with the New York Attorney General over misleading sales tactics. The drug is effectively off the commercial market.
OPVEE nalmefene hydrochloride Updated Oct 29
What to watch
OPVEE by itself has no catalysts left to watch. For INDV stock, the near-term events are the Supernus merger closing (expected November 2, 2026), after which the combined company will trade under ticker SUPN. The merger makes OPVEE's commercial failure even less relevant, as the combined entity will have a diversified CNS pipeline beyond opioid-use-disorder products.
Bull case
- OPVEE was the first FDA-approved nalmefene nasal spray for opioid overdose, differentiated from naloxone by a longer duration of action that could theoretically be advantageous against potent synthetic opioids like fentanyl.
- The FDA approval was a scientific/regulatory validation of nalmefene as an alternative to naloxone for overdose rescue.
Bear case
- Indivior discontinued all marketing and promotion of OPVEE in September 2025, following a settlement with the New York Attorney General over allegations it misled public officials about the drug's authorization and effectiveness.
- OPVEE was a commercial failure: it generated meager sales and was never adopted by health departments or harm-reduction organizations who preferred naloxone (Narcan), which is available over-the-counter and has a better safety profile.
- Harm reduction advocates actively opposed OPVEE, arguing it caused more severe withdrawal symptoms than naloxone and offered no meaningful advantage at a higher price.